Health & Wellness

Press Releases

Brain Cancer Study Opens at Overlook Medical Center - One of Four Sites in Country

84c7598a938691beaecb_Dr._Kurt_Jaeckle_preferred_2017.jpg
84c7598a938691beaecb_Dr._Kurt_Jaeckle_preferred_2017.jpg

Kurt Jaeckle, MD, co-director of the Gerald J. Glasser Brain Tumor Center at Overlook Medical Center, and medical director of the Atlantic Center for Research, is leading a phase III study of novel drug VAL-083, which has already shown promise in Glioblastoma and other cancers. 

The study is for patients whose glioblastoma multiforme or gliosarcoma has progressed during or after treatment with the standard of care chemo-radiation therapy. Other study locations are: Kaiser Permanente Los Angeles Medical Center; University of California, San Francisco; and Dent Neurosciences Research Center, Amherst, NY.

“Glioblastoma is very difficult to treat, and I am encouraged by previously reported results with VAL-083,” said Dr. Jaeckle.  “I am also happy that some of the most innovative pharmaceutical companies are looking to Atlantic Health System when they seek to test new types of treatments for brain tumors. The availability of this and other neuro-oncology clinical trials provides a benefit to our patients, and gives me hope for the future.”

Sign Up for E-News

Glioblastoma is the most common and most aggressive type of brain cancer, with typical survival of 14-20 months for newly diagnosed patients. Standard treatment includes surgery to remove as much of the tumor as is safely possible, followed by radiation therapy and chemotherapy with temozolomide. Nearly all glioblastoma patients will relapse.Gliosarcoma, which is also being studied in this clinical trial, is a rare and equally aggressive form of glioblastoma. 

VAL-083 is a first-in-class small molecule chemotherapy drug. This means that the molecular structure of VAL-083 is not similar in chemical structure (an analogue) or derivative of other small molecule chemotherapeutics approved for the treatment of cancer. VAL-083 is unique in that it has been shown to overcome cancer cells’ resistance to MGMT, a DNA-repair mechanism that causes recurrent glioblastoma to resist treatment with temozolomide. Many glioblastoma tumors express large amounts of MGMT, making them difficult to treat with currently available chemotherapies.

According to DelMar Pharmaceuticals, VAL-083 has been assessed in 42 Phase I and Phase II clinical trials sponsored by the National Cancer Institute as a treatment against various cancers. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types, including lung, brain, cervical, ovarian tumors and hematologic (blood) cancers.  Earlier clinical trials have shown that VAL-083 is comparable or superior to other chemotherapies in treating glioblastoma.

To learn more about study inclusion and exclusion criteria, go to the Atlantic Center for Research: research.atlantichealth.org/VAL_083.

About the Gerald J. Glasser Brain Tumor Center

Specialists at the Gerald J. Glasser Brain Tumor Center treat a variety of brain tumors and related conditions, including acoustic neuromas and schwannomas; anaplastic astrocytomas, oligodendrogliomas and low-grade gliomas; brain, epidural and leptomeningeal metastases; ependymomas; glioblastomas; low-grade astrocytomas; lymphomas; meningiomas; medulloblastomas; peripheral nerve, pineal and pituitary tumors; rare glial and neuronal tumors; sarcomas; and spinal cord tumors. The center features a multidisciplinary panel of experts who specialize in neurosurgery, skull base surgery, neuroradiology, radiation oncology, neuro-oncology, medical oncology, neurology, neuropathology and social work. Overlook Medical Center also has the largest CyberKnife® program in the tri-state area for the treatment of brain tumors. The brain tumor center recently moved into its own space on the main level of Overlook Medical Center, in order to foster an optimal, convenient patient-centered experience.

Dr. Jaeckle sees patients at the Gerald J. Glasser Brain Tumor Center of Overlook Medical Center’s Atlantic Neuroscience Institute and Carol G. Simon Cancer Center, 99 Beauvoir Avenue, Summit, NJ. He and other members of the Gerald J. Glasser Brain Tumor Center can be reached at (908) 516-2941. For more information on this clinical trial or other studies, please call the Atlantic Center for Research at (973) 971-5235.

TAP Into Another Town's News:

You May Also Be Interested In

Sign Up for E-News

Roxbury

Columns

AtlantiCast

AtlantiCast: Episode 16

Summer is in the air, and the latest episode of AtlantiCast is ready to help you enjoy some fun outdoors while staying safe! This week’s episode opens with tips for sunscreen usage from Atlantic Health System’s Chief Medical and Academic Officer, Dr. Jan Schwarz-Miller. You’ll also learn about how Atlantic Health System is advancing the future of health care through ...

Letters to TAPinto Roxbury

Necessary Discussion and Debate of Addressing School Violence

June 10, 2018

Dear Editor,

As of late, due to most disturbing acts of violence against children in our schools, there is much vigorous debate regarding gun control and protection of our children and grand-children.

Much of the debate is based on emotion rather than reasoned thought.

I think that exploration in three areas needs to be more thoroughly discussed and debated. The first is ...

Necessary Discussion and Debate of Addressing School Violence

Dear Editor,

As of late, due to most disturbing acts of violence against children in our schools, there is much vigorous debate regarding gun control and protection of our children and grand-children.

Much of the debate is based on emotion rather than reasoned thought.

I think that exploration in three areas needs to be more thoroughly discussed and debated. The first is ...

22 From Roxbury Area Make U of Delaware Dean's List

June 15, 2018

NEWARK, DE - The following Roxburyuarea students have been named to the University of Delaware Dean's List for the Spring 2018 semester:

Samantha Aquino of Flanders 

Olivia Boon of Ledgewood 

Christopher Bouvier of Flanders 

Alyssa Cartier of Flanders 

Juliette Castro of Landing 

Brennan Chuprinko of Flanders 

Ryan Decker of ...

Roxbury Student Makes University of Hartford Dean's List

WEST HARTFORD, CT - The University of Hartford is pleased to announce Zachary Almakias of Succasunna has been named to its Dean's List for Spring 2018.

Nicole Peterson of Roxbury Graduates from Widener

CHESTER, PA -- Nicole Peterson of Succasunna was one of more than 800 to graduate May 19 from Widener University.

Peterson earned a Bachelor of Social Work in Social Work from Widener's School of Human Service Professions.

Widener University is a private, metropolitan university that connects curricula to social issues through civic engagement. Dynamic teaching, active scholarship, ...

Press Releases

JCP&L Completes Inspections and Projects Prior to Summer Season to Help Enhance Customer Service Reliability

June 11, 2018

Jersey Central Power & Light (JCP&L) has completed inspections and projects across its 13-county service area to enhance customer reliability in preparation for the summer season.  The work included upgrading transmission and substation equipment, upgrading circuits and trimming trees along power lines. 

Helicopter patrols are completing inspections on more than 780 ...

Facebook Provides Verification Badges for All TAPinto Facebook Pages

TAPinto and its 75 partner sites have been verified on Facebook with the social media platform's blue badge, which is given to news organizations that meet Facebook's authenticity criteria. 

Facebook gives the blue verification badge to "eligible brands, media organizations and public figures," based on factors that include policy compliance and public ...